search for




 

Comparison of Usage Patterns and Outcomes by Dual Type Calcium Channel Blockers in Patients with Chronic Kidney Disease
Korean J Clin Pharm 2020;30(4):259-263
Published online December 31, 2020
© 2020 Korean College of Clinical Pharmacy.

Mi Ran Oh1, Hye Lim Ahn1, Sun Choi2, and Hyen Oh La3 *

1Department of Pharmacy, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
2Catholic Medical Center Office of Human Research Protection, Seoul 06591, Republic of Korea
3College of Pharmacy, the Catholic University of Korea, Gyeonggi-do 14662, Republic of Korea
Correspondence to: Hyen Oh La, College of Pharmacy, the Catholic University of Korea, 43 Jibong-ro, Bucheon-si, Gyeonggi-do 14662, Republic of Korea
Tel: +82-2-2164-6598, Fax: +82-2-2164-4059
E-mail: hola@catholic.ac.kr
Received August 10, 2020; Revised December 11, 2020; Accepted December 12, 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Dual-type calcium channel blockers (CCBs), such as efonidipine and cilnidipine, are renoprotective drugs that reportedly reduce proteinuria by dilating afferent and efferent arterioles of the glomerulus. However, studies comparing the effect of dual-type CCB on proteinuria have not been conducted. Therefore, we aimed to compare the effect of dual-type CCB (efonidipine and cilnidipine) usage patterns in hypertensive patients with chronic kidney disease (CKD). Methods: This single-center, retrospective study included 53 patients with CKD who 1) initiated efonidipine or cilnidipine treatment while on a renin-angiotensin system inhibitor and 2) had received efonidipine or cilnidipine for at least one year. We compared usage patterns between the efonidipine and cilnidipine groups during the one-year period and analyzed the following outcomes: urinary protein-to-creatinine ratio, blood pressure, and serum creatinine. Results: The study included 25 patients in the efonidipine group and 28 patients in the cilnidipine group. In both groups, blood pressure and urinary protein-to-creatinine ratios tended to decrease; however, the change during each interval was not significant. Conclusions: In patients with CKD who were on renin-angiotensin system inhibitor therapy, the addition of a dual-type CCB (i.e., efonidipine or cilnidipine) tended to reduce proteinuria; however, the change during each interval was not significant.
Keywords : Chronic kidney disease, proteinuria, efonidipine, cilnidipine, calcium channel blocker


December 2020, 30 (4)
Full Text(PDF) Free

Social Network Service
Services

Cited By Articles
  • CrossRef (0)